183 related articles for article (PubMed ID: 10430428)
1. Striatal presynaptic monoaminergic vesicles are not increased in Tourette's syndrome.
Meyer P; Bohnen NI; Minoshima S; Koeppe RA; Wernette K; Kilbourn MR; Kuhl DE; Frey KA; Albin RL
Neurology; 1999 Jul; 53(2):371-4. PubMed ID: 10430428
[TBL] [Abstract][Full Text] [Related]
2. Increased ventral striatal monoaminergic innervation in Tourette syndrome.
Albin RL; Koeppe RA; Bohnen NI; Nichols TE; Meyer P; Wernette K; Minoshima S; Kilbourn MR; Frey KA
Neurology; 2003 Aug; 61(3):310-5. PubMed ID: 12913189
[TBL] [Abstract][Full Text] [Related]
3. Decreased striatal monoaminergic terminals in Huntington disease.
Bohnen NI; Koeppe RA; Meyer P; Ficaro E; Wernette K; Kilbourn MR; Kuhl DE; Frey KA; Albin RL
Neurology; 2000 May; 54(9):1753-9. PubMed ID: 10802780
[TBL] [Abstract][Full Text] [Related]
4. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging.
Frey KA; Koeppe RA; Kilbourn MR; Vander Borght TM; Albin RL; Gilman S; Kuhl DE
Ann Neurol; 1996 Dec; 40(6):873-84. PubMed ID: 9007092
[TBL] [Abstract][Full Text] [Related]
5. Striatal [11C]dihydrotetrabenazine and [11C]methylphenidate binding in Tourette syndrome.
Albin RL; Koeppe RA; Wernette K; Zhuang W; Nichols T; Kilbourn MR; Frey KA
Neurology; 2009 Apr; 72(16):1390-6. PubMed ID: 19380698
[TBL] [Abstract][Full Text] [Related]
6. Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine.
Koeppe RA; Frey KA; Kuhl DE; Kilbourn MR
J Cereb Blood Flow Metab; 1999 Dec; 19(12):1376-84. PubMed ID: 10598942
[TBL] [Abstract][Full Text] [Related]
7. VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET.
De La Fuente-Fernández R; Furtado S; Guttman M; Furukawa Y; Lee CS; Calne DB; Ruth TJ; Stoessl AJ
Synapse; 2003 Jul; 49(1):20-8. PubMed ID: 12710012
[TBL] [Abstract][Full Text] [Related]
8. Decreased striatal monoaminergic terminals in severe chronic alcoholism demonstrated with (+)[11C]dihydrotetrabenazine and positron emission tomography.
Gilman S; Koeppe RA; Adams KM; Junck L; Kluin KJ; Johnson-Greene D; Martorello S; Heumann M; Bandekar R
Ann Neurol; 1998 Sep; 44(3):326-33. PubMed ID: 9749598
[TBL] [Abstract][Full Text] [Related]
9. Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine.
Teng L; Crooks PA; Dwoskin LP
J Neurochem; 1998 Jul; 71(1):258-65. PubMed ID: 9648873
[TBL] [Abstract][Full Text] [Related]
10. In vivo measurement of the vesicular monoamine transporter in schizophrenia.
Taylor SF; Koeppe RA; Tandon R; Zubieta JK; Frey KA
Neuropsychopharmacology; 2000 Dec; 23(6):667-75. PubMed ID: 11063922
[TBL] [Abstract][Full Text] [Related]
11. Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using (+)-alpha-[11C]dihydrotetrabenazine (DTBZ) and positron emission tomography.
Koeppe RA; Frey KA; Kume A; Albin R; Kilbourn MR; Kuhl DE
J Cereb Blood Flow Metab; 1997 Sep; 17(9):919-31. PubMed ID: 9307605
[TBL] [Abstract][Full Text] [Related]
12. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
Kilbourn MR; Kuszpit K; Sherman P
Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
[TBL] [Abstract][Full Text] [Related]
13. Decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography.
Gilman S; Frey KA; Koeppe RA; Junck L; Little R; Vander Borght TM; Lohman M; Martorello S; Lee LC; Jewett DM; Kilbourn MR
Ann Neurol; 1996 Dec; 40(6):885-92. PubMed ID: 9007093
[TBL] [Abstract][Full Text] [Related]
14. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
Suzuki M; Desmond TJ; Albin RL; Frey KA
Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403
[TBL] [Abstract][Full Text] [Related]
15. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease.
Miller GW; Erickson JD; Perez JT; Penland SN; Mash DC; Rye DB; Levey AI
Exp Neurol; 1999 Mar; 156(1):138-48. PubMed ID: 10192785
[TBL] [Abstract][Full Text] [Related]
16. Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?
Boileau I; Rusjan P; Houle S; Wilkins D; Tong J; Selby P; Guttman M; Saint-Cyr JA; Wilson AA; Kish SJ
J Neurosci; 2008 Sep; 28(39):9850-6. PubMed ID: 18815269
[TBL] [Abstract][Full Text] [Related]
17. Reproducibility studies with 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects.
Chan GL; Holden JE; Stoessl AJ; Samii A; Doudet DJ; Dobko T; Morrison KS; Adam M; Schulzer M; Calne DB; Ruth TJ
J Nucl Med; 1999 Feb; 40(2):283-9. PubMed ID: 10025836
[TBL] [Abstract][Full Text] [Related]
18. Vesicular monoamine transporter-2: immunogold localization in striatal axons and terminals.
Nirenberg MJ; Chan J; Liu Y; Edwards RH; Pickel VM
Synapse; 1997 Jun; 26(2):194-8. PubMed ID: 9131778
[TBL] [Abstract][Full Text] [Related]
19. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium.
Staal RG; Hogan KA; Liang CL; German DC; Sonsalla PK
J Pharmacol Exp Ther; 2000 May; 293(2):329-35. PubMed ID: 10772999
[TBL] [Abstract][Full Text] [Related]
20. Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users.
Little KY; Krolewski DM; Zhang L; Cassin BJ
Am J Psychiatry; 2003 Jan; 160(1):47-55. PubMed ID: 12505801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
